CONMED - CNMD Stock Forecast, Price & News

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of CONMED from a "sell" rating to a "hold" rating in a research report on Tuesday.

CONMED Trading Up 3.5 %

Shares of NASDAQ:CNMD traded up $3.45 during mid-day trading on Wednesday, reaching $100.85. The stock had a trading volume of 315,507 shares, compared to its average volume of 370,029. The company has a market cap of $3.07 billion, a price-to-earnings ratio of -24.60, a PEG ratio of 2.63 and a beta of 1.49. The stock has a 50 day moving average of $98.36. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.43 and a current ratio of 2.87. CONMED has a twelve month low of $87.24 and a twelve month high of $159.11.

CONMED (NASDAQ:CNMD - Get Rating) last announced its quarterly earnings results on Wednesday, July 27th. The company reported $0.76 earnings per share for the quarter, meeting analysts' consensus estimates of $0.76. The business had revenue of $277.19 million for the quarter, compared to the consensus estimate of $273.78 million. CONMED had a negative net margin of 10.93% and a positive return on equity of 13.94%. On average, equities analysts anticipate that CONMED will post 3.32 EPS for the current fiscal year.